Dr. Park is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2220 Pierce Avenue
PRB 698
Nashville, TN 37232Phone+1 615-936-1919- Is this information wrong?
Summary
- Dr. Ben Park is an oncologist in Nashville, TN. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 21 years. He specializes in breast cancer and is experienced in breast cancer, and cancer genetics.
Education & Training
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1997 - 2000
- University of Pennsylvania Health SystemResidency, Internal Medicine, 1995 - 1997
- The University of PennsylvaniaPh.D., Immunology, 1989 - 1995
- Perelman School of Medicine at the University of PennsylvaniaClass of 1995
- The University of Chicago with HonorsBA, Biology, 1985 - 1989
Certifications & Licensure
- MD State Medical License 2002 - 2025
- TN State Medical License 2018 - 2025
- PA State Medical License 1996 - 2002
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Robin Prothro Passion for the Promise Award Susan G. Komen, Maryland, 2018
- VIP Marshall School of Medicine Commencement, 2018
- Cancer Center Director�s Teaching Award in Laboratory Science 2018
- Join now to see all
Publications & Presentations
PubMed
- 21 citationsCollaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical Practices.Shruti Rao, Beth A. Pitel, Alex H. Wagner, Simina M. Boca, Matthew McCoy
JCO Clinical Cancer Informatics. 2020-07-09 - 19 citationsPrevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.Bedri Karakas, Dilek Colak, Namik Kaya, Hazem Ghebeh, Abeer Al-Qasem
Cancer Biology & Therapy. 2013-08-12 - 35 citationsBiomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.N Lynn Henry, Mark R Somerfield, Zoneddy Dayao, Anthony Elias, Kevin Kalinsky
Journal of Clinical Oncology. 2022-09-20
Journal Articles
- High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patientsAlhuqail AJ, Alzahrani A, Almubarak H, Al-Qadheeb S, Alghofaili L, Almoghrabi N, Alhussaini H, Park BH, Colak D, Karakas B., Breast Cancer Res Treat, 1/1/2018
- PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneityCroessmann S, Wong HY, Zabransky DJ, Chu D, Rosen DM, Cidado J, Cochran RL, Dalton WB, Erlanger B, Cravero K, Button B, Kyker-Snowman K, Hurley PJ, Lauring J, Park BH, Breast Cancer Res Treat, 1/1/2017
- Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor BoardDalton B, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson E, S..., JCO Precision Oncology, 1/1/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Cell versus Cell-Free Candidate BiomarkersPark BH, American Society of Clinical Oncology (ASCO) Annual meeting, Chicago, IL, 1/1/2014
Lectures
- Breast Cancer Mutations as Diagnostic and Therapeutic Targets for TherapyUniversity of North Carolina, Chapel Hill, NC - 1/1/2019
- Precision Breast Oncology: Genes to DrugsThe Mayan Riveria, Mexico - 1/1/2019
- Mutations in breast cancer as diagnostic and therapeutic targetsBaltimore, MD - 1/1/2018
- Join now to see all
Other
- Guide 2 ChemoShockney L, Park BH
http://www.guide2chemo.com/
1/1/2009 - Mutations in cancer cellsAvon Foundation Breast Care Fund Presentation
1/1/2007
Press Mentions
- Blood-Based 'Liquid Biopsy' Might Spot Early-Stage CancersApril 17th, 2023
- Underpinning the Advances, Challenges to Democratizing Precision OncologyDecember 3rd, 2022
- New Clinician Spotlight: Laura KennedyApril 16th, 2021
- Join now to see all
Grant Support
- Molecular Targets For Cancer Detection And TreatmentNational Cancer Institute2011
- Genetic Effectors Of Tgf-Beta Induced Growth And Arrest.National Cancer Institute2006–2010
- Genetic Effectors Of Tgf-Beta Induced Growth And ArrestNational Cancer Institute2007
- Genetic Effectors Of Tgf-Beta Induced Growth And ArrestNational Cancer Institute2005
Professional Memberships
- Member
- Member
- American Society of Clinical InvestigationMember
External Links
- Vanderbilt University Medical Centerhttps://medicine.mc.vanderbilt.edu/person/ben%20ho-park
- Park Lab webpagehttp://benhopark.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: